Dulaglutide

GPTKB entity

Statements (61)
Predicate Object
gptkbp:instance_of gptkb:pharmaceuticals
gptkbp:administered_by subcutaneous injection
gptkbp:approves gptkb:2014
gptkb:FDA
gptkbp:brand gptkb:Trulicity
gptkbp:chemical_formula C172 H265 N43 O51 S
gptkbp:class antidiabetic agent
gptkbp:clinical_trial Phase 3
gptkbp:clinical_use chronic management of diabetes
gptkbp:contraindication gptkb:multiple_endocrine_neoplasia_syndrome_type_2
gptkb:medullary_thyroid_carcinoma
gptkbp:developed_by gptkb:Eli_Lilly_and_Company
gptkbp:dosage_form pre-filled pen
gptkbp:frequency once a week
https://www.w3.org/2000/01/rdf-schema#label Dulaglutide
gptkbp:indication weight management
gptkbp:ingredients gptkb:Dulaglutide
gptkbp:interacts_with gptkb:diabetes
sulfonylureas
gptkbp:lifespan 5 days
gptkbp:market ongoing
gptkbp:marketed_as gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
gptkbp:mechanism_of_action gptkb:SS
gptkbp:patient_education diet and exercise
monitoring blood sugar
injection technique
gptkbp:patient_population adults
gptkbp:pharmacokinetics glucose-dependent insulin secretion
once-weekly dosing
gptkbp:provides_guidance_on recommended for type 2 diabetes
gptkbp:research_focus patient quality of life
mechanism of action studies
drug interactions
real-world evidence studies
safety in special populations
long-term cardiovascular outcomes
renal outcomes
weight loss efficacy
health economic evaluations
comparative effectiveness studies
compliance and adherence
gptkbp:route_of_administration subcutaneous
gptkbp:safety_labeling_changes gptkb:2019
gptkbp:side_effect nausea
abdominal pain
vomiting
diarrhea
hypoglycemia
pancreatitis
kidney injury
gptkbp:storage refrigerated
gptkbp:trade gptkb:Trulicity
gptkbp:type_of_care important for efficacy
gptkbp:used_for type 2 diabetes
gptkbp:weight 249.3 k Da
gptkbp:bfsParent gptkb:Metformin
gptkb:Dapagliflozin
gptkbp:bfsLayer 5